Clinical Trial

A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

Study acronym: NOVA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of the trial is to evaluate the efficacy of vipoglanstat on endometriosis-related non-menstrual pelvic pain (NMPP).
Protocol Amendment History 1 change
notable Trial sites expanded: 30 -> 41 locations 2026-04-18
Trial Details
NCT Number NCT07260669
Lead Sponsor Gesynta Pharma AB
Conditions Endometriosis
Enrollment 190 participants
Start Date 2025-10-15
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-04-17